

HYPERTENSION CANADA

ANNUAL REPORT 2022





TABLE OF CONTENTS

INTRODUCTION

President's Report	2
Executive Director's Report	4

OVERVIEW

About Hypertension Canada	6
Strategic Plan 2022-2025	8
MVP Statement	10

GOVERNANCE

Board of Directors	12
---------------------------	----

COMMITTEES

Committee Lists	16
Committee Reports	19

FINANCES

Financial Overview	28
---------------------------	----



PRESIDENT'S REPORT

Dr. Ross T. Tsuyuki

1. Update on 2020-2022 Strategic Plan Priorities:

(a). Hypertension Canada – Professional Certification Program (HC-PCP)

- Registrations to date: 121 (full program), Level 1: 62, Level 2: 7
- Total of \$169,025 in registration fees in the past year.
- Servier (Gulf States): We are delivering a modified version of the PCP (without certification) in the Middle East.
- Bulk purchases from pharmacy chains: Shoppers Drug Mart has purchased some registrations (50 as a start), we have approached other chains for bulk purchase.
- RxPATH (randomized trial of the HC-PCP in Alberta) has been completed, and was presented at the International Society of Hypertension meeting in Kyoto in October. In this trial, we randomized pharmacists taking care of patients with hypertension to receive the HC-PCP or not. Patients of those pharmacists who had taken the HC-PCP had a 5.5mmHg lower systolic blood pressure!

(b). HC Device Recommendation Program:

- Revenue of \$395,092 in the past year.
- We have re-launched the DRP committee, with Dr. Swapnil Hiremath chairing. There is a lot of opportunity here.

(c). New strategic plan (2022-2025) was created in February, 2022.

Vision: Healthy blood pressure for every Canadian.

Mission: Advancing the health of Canadians by enabling the detection, prevention and control of high blood pressure and its complications.

Focus will be on 2 important objectives:

1. Be the trusted voice for hypertension and cardiovascular risk.
2. Obtain baseline data on blood pressure health in Canada and develop a tracking system to monitor trends over time

There are numerous activities that are associated with these objectives and we will be looking for some help with getting them going. Please read the full strategic plan for more details:

<https://hypertension.ca/about-us/#strategic>

2. Financial position

After 2 years of hard work and restructuring, I am pleased to say that we are in a much better financial situation (see the financial report by Trevor Hudson).

3. Canadian Hypertension Congress and Young Investigator Forum

The Forum was held virtually on May 5-6, 2022. We had 193 attendees, and evaluations were very positive. Next year's congress will likely be held in conjunction with Vascular 2023, in partnership with the Canadian Cardiovascular Society, Diabetes Canada, Diabète Québec, Thrombosis Canada, and the Canadian Society of Endocrinology and Metabolism. Hold the date for October 26-27 in Montreal.

4. Board of Directors

Many thanks to outgoing board members Dr. Alan Bell, Dr. Rob Gros, Ms. Dorothy Morris and Mr. Trevor Hudson. Thank you for your service! We have an exceptional slate of new director candidates

5. We need your help

We are volunteer-driven and our programs depend on you. Please contact me if you see anything you're interested in working on (or have suggestions).

Respectfully submitted,

ROSS T. TSUYUKI, BSS (PHARM), PHARMD, MSC, FCSHP, FACC FCAHS, ISHF

Chair of the Board



EXECUTIVE DIRECTOR'S REPORT

Asif Ahmed

There has been a lot of development since my last report to you. Even though the pandemic is still with us, I would like to think that all of us have managed to live with it one way or the other. A lot of us have started to go back to our respective workplaces in some capacity and we are seeing a lot of in-person events happening around us. Speaking of events, even though HC's 2022 Congress and YI Forum was held virtually in May, we hope that was the last of it. This year's theme was "Hypertension and Cardiovascular Prevention". The event was a huge success. We had an excellent lineup of sessions showcasing cutting-edge research abstracts, addressed knowledge gaps head-on, and inspired innovation through open exchange to drive improved health outcomes for people living with hypertension and cardiovascular risks. Next year, we are partnering with the Canadian Cardiovascular Society (CCS) and several other organizations to present "Vascular 2023" in October at The Palais des congrès de Montréal. I hope to see you in-person at the event.

I am very happy to report that HC has its new 2022-25 strategic plan. The board worked very hard to develop it earlier this year. Now we are busy working on its implementation. We have also developed our Member Value Proposition which articulates how we intend to create value for our members.

Financially, we're on a sound footing. We have continued to manage our expenses prudently and increase our revenue. We have developed partnerships with various local and international organizations for our Professional Certification Program (PCP), whereby we arm their pharmacists with the knowledge and confidence to identify and manage patients with hypertension. Through online learning modules and practical applications using real-world patient cases, this comprehensive certification program provides the opportunity to examine and execute the core competencies of hypertension management to improve patient care.

We have relaunched our Device Recommendation Program committee which is responsible for updating the processes of the program, which has been a huge success since its launch in 2017.

On the governance side, it's a bittersweet moment for us. On one hand, we are looking forward to welcoming three new board members and on the other, sad to see our two very dear members leave the board after completing their full terms. I would like to thank Ms. Dorothy Morris and Mr. Trevor Hudson for their dedication and hard work that they put in over the course of the last 8 years. We need more volunteers like them. Earlier on, we saw two of our other board members, Drs. Alan Bell and Rob Gros, leave. I would like to take this opportunity to thank both of them for their hard work and dedication.

In closing, I would like to thank you, our members, for being a part of Hypertension Canada and your continued commitment to the mission and vision of the association.

Thank you,

ASIF AHMED

Executive Director

ABOUT HYPERTENSION CANADA

Hypertension Canada is the only national non-profit organization dedicated solely to the prevention and control of hypertension and its complications.

We work with leading minds across medical and health disciplines to advance research and professional and public education, and with policy makers to ensure Canadians can avoid the potentially deadly complications of hypertension.

Seven and a half million people in Canada, about 1 in 5 adults, live with hypertension. Rising blood pressure over the long term causes atherosclerosis – the main risk for premature death (before the age of 65).

Canada has become a leader in the early detection of high blood pressure, its treatment and overall management. Much of this success has been attributed to the Hypertension Canada Guidelines – a set of clinical practice guidelines which are rigorously reviewed and updated regularly,

providing health care professionals with the most up-to-date recommendations and guidelines for the detection, treatment and control of hypertension.

Despite recent achievements, 1 in 3 people with hypertension have uncontrolled blood pressure, particularly high-risk patients with diabetes and kidney disease; and almost 1 in 5 people with hypertension are unaware of their condition.



STRATEGIC PLAN 2022-2025

FEBRUARY 2022

Mission & Vision

Hypertension Canada modified its mission and vision to reflect the current climate.

Mission

Advancing the health of Canadians by enabling the detection, prevention and control of high blood pressure and its complications.

Vision

Healthy blood pressure for every Canadian.

Mandate

Hypertension Canada delivers its mission/vision by striving for excellence in three core service areas:

- Research: Knowledge generation through research and innovation.
- Education: Knowledge translation by turning discovery into practice.
- Government & Stakeholder Relations: Creating supportive environments through healthy public policy and lifestyles.

Strategic Plan – 2022-2025

Hypertension Canada developed its new 3-year strategic plan earlier this year.

1. Be the trusted voice for hypertension and cardiovascular risk.
 - a. Make HC's website the single, authoritative point of contact for health care professionals and the general public, to get guidance and information about hypertension.
 - b. Build partnerships with like-minded organizations (e.g., Heart and Stroke Foundation, Canadian Cardiovascular Society) so that HC provides all of their hypertension content in return for attribution.

2. Obtain baseline data on blood pressure health in Canada and develop a tracking system to monitor trends over time.

Objective 1

Be the trusted voice for hypertension and cardiovascular risk.

Why

This supports HC's vision "Healthy blood pressure for every Canadian."

Actions

1. Strike a Hypertension Resources Task Force with accountability for HC website content.
2. Review resources/content on HC website and update where appropriate.
3. Appoint a web design company to format the new content and optimize the pages for public web traffic. Consider organic and paid options to attract traffic.
4. Consider striking a focus group of health care professionals and patients to review the results and provide input.
5. Strike a Hypertension Partnerships Task Force with the following accountability:
 - a. Identify like-minded partners.
 - b. Create a proposal to provide their hypertension content.
 - c. Get board approval for prospective partners and proposal.
 - d. Reach out to prospective partners with HC's proposal.

Objective 2

Obtain baseline data on Canadian blood pressure health and develop a tracking system to monitor trends over time.

Why

This supports HC's vision "Healthy blood pressure for every Canadian."

Actions

1. Assign accountability for managing this priority to the Research and Evaluation Committee. The committee is to complete the research below and return to the board with a recommendation and suggest an appropriate budget.
 - a. Find out if the Canadian health measures survey is still taking place.
 - b. If so, determine how to liaise with them to gain access to the data.
 - c. If not, determine how best to collect this data.
 - i. What are other countries doing? Is there a model we can use?
 - ii. Can we solicit test participants via public survey and then use the pharmacy infrastructure for testing?
2. Approve or revise Task Force recommendation and budget.
3. Execute plan.

HC MEMBER VALUE PROPOSITION STATEMENT

By joining HC, you will:

Be welcomed into a community of like-minded individuals, working together to reduce the burden of high blood pressure and its complications.

- Contribute to knowledge transfer and education.
- Access a diverse platform of awards recognizing excellence.
- Showcase the next generation of hypertension professionals.
- Communicate new discoveries in hypertension treatment and management.
- Receive curated knowledge and timely updates.
- Raise your profile and advance your career.



BOARD OF DIRECTORS 2021-2022



Dr. Ross T. Tsuyuki
President



Dr. Shelita Dattani
Board Member



David Henley
Board Member



Trevor Hudson
Treasurer



Dorothy Morris
Board Member



Dr. Laurie K Taylor
Board Member

BOARD OF DIRECTORS BIOGRAPHIES

Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC, FCAHS
President
Edmonton, Alberta

Dr. Ross Tsuyuki is Professor and Chair, Department of Pharmacology in the Faculty of Medicine and Dentistry, University of Alberta. He is also a Professor of Medicine (Cardiology) and Director of EPICORE Centre (a health research coordinating centre) and the Editor-in-Chief of the Canadian Pharmacists Journal. His clinical practice is in the Heart Function Clinic at the Mazankowski Alberta Heart Institute. Having previously served on Hypertension Canada’s Board of Directors, Dr. Tsuyuki was elected in 2019 and appointed Vice-President. He also serves as a Co-Chair of the Education & Implementation Committee and is a member of the Hypertension Canada Guidelines Committee.

Dr. Tsuyuki’s interests are in clinical trials design and execution, hypertension, heart failure, community practice-based research, cardiovascular risk factors, and in the provision of support for clinical researchers through the EPICORE Centre. Dr. Tsuyuki has received several awards for teaching, as well as an appointment as a Fellow of the Canadian Society of Hospital Pharmacists, the American College of Cardiology and the Canadian Academy of Health Sciences. In 2005, he was recognized as the Canadian Pharmacist of the Year by the Canadian Pharmacists Association.

Trevor Hudson, CA
Treasurer
Oakville, Ontario

Trevor is a lead tax services partner in the Corporate Tax practice in Toronto and is the national industry tax leader for the Infrastructure and Real Estate Sector. Trevor has over 20 years of professional experience in public practice and provides tax advisory services to Canadian and foreign based clients on matters relating to corporate tax planning, corporate reorganizations, mergers and acquisitions, tax accounting, and tax compliance reporting.

Trevor works with a range of clients, which include infrastructure and real estate funds, REITs, private equity funds, infrastructure and real estate developers, and energy funds on matters relating to corporate structuring, project structuring, bid evaluations and tax modeling. He also advises private sector and government sponsors on P3 project procurement and development. Trevor’s extensive experience in these sectors has included working with government and private sector investors on projects relating to energy, airports, roads and bridges, public transit, hospitals, court houses, correctional facilities, concert halls, and other similar assets.

Trevor is a Chartered Professional Accountant and his education includes a Master of Taxation, a Master of Business Administration (Finance), and a Bachelor of Science in Biochemistry.

Shelita Dattani, BSc.PhM., Pharm.D
Ottawa, Ontario

Dr. Shelita Dattani is the Vice President of Pharmacy Affairs at the Neighbourhood Pharmacy Association of Canada and in this role she leads a team advocating for pharmacy's evidence-based role in delivering accessible, high-quality healthcare and building capacity in public health and primary care.

Sheli received her Bachelor of Science in Pharmacy from Northeastern University and her Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill. Sheli is a pharmacist with over 20 years' experience in many sectors of the profession, including community, hospital, academia, industry, group purchasing organizations and professional and pharmacy associations.

Sheli maintains a part-time practice in primary care team-based practice, community pharmacy, and remote hospital telepharmacy. Sheli also serves as a lecturer at The Memorial University of Newfoundland and as a guest lecturer at The University of Waterloo in their Doctor of Pharmacy Programs. She is passionate about her continued engagement as a preceptor, teacher and educator and is draws inspiration from her roles supporting students and pharmacists in their professional development. Sheli is committed to contributing to pharmacy's growing role as an integral health care partner.

Dorothy Morris, RN, BSN, MA, CCN(C)
Victoria, British Columbia

Ms. Dorothy Morris is a clinical nurse educator in cardiac surgery and coronary care at the Royal Jubilee Hospital, Victoria, British Columbia and Canadian Council of Cardiovascular Nurses (CCCN)'s National director for health promotion and advocacy. Ms. Morris was elected to Hypertension Canada's Board in 2014.

Ms. Morris has co-authored and teaches a basic arrhythmia interpretation and management course, speaks on a variety of cardiovascular topics and has published a number of articles.

She has given numerous presentations at national and international conferences including the Canadian Association of Gerontology, The International Society of Hypertension, and the Canadian Cardiovascular Congress. She contributes to the work of Hypertension Canada and the Canadian Institutes of Health Research / Heart and Stroke Foundation Chair's Hypertension Advisory Committee.

In 2005, Ms. Morris received the award of excellence for nursing education from the college of registered nurses of British Columbia and the clinical cardiovascular excellence award from CCCN. She has also been the recipient of an award of excellence from Hypertension Canada and award of merit for workplace health innovation from the health employers association of British Columbia.

Ms. Morris has a keen interest in cardiovascular disease risk factors, health advocacy and in continuing nursing education initiatives.

David G. Henley, Q.C.
Halifax, Nova Scotia

David currently works both as part-time General Counsel to Acadian Seaplants Limited and part-time Counsel to Irving Shipbuilding providing support for key legal issues. Previously, he was the Vice President and General Counsel at Irving Shipbuilding from 2015 to 2019. From 2001 to 2015, he was a partner in the Halifax office of Stewart McKelvey where he had a broad commercially oriented practice in maritime, construction, energy and natural resources, and environmental law. Before law, David had a career in the army as an artillery officer. He continued to serve in the Army Reserve while practicing law and after returning from a tour in Afghanistan in 2010 was invested as a member of the Order of Military Merit by the Governor-General. He retired from the Army in 2015 as a Brigadier-General after 30 years of full and part-time service. His last position was Deputy Commander for the 5th Canadian Division, essentially the Army in Atlantic Canada. He has written, presented and published papers and contributed to books on various marine and environment subjects. David is an associate of the Marine Environmental Law Institute and was a member of the part-time faculty at the Schulich School of Law where he taught Fisheries Law from 2004 to 2015. He was a member of the Transportation Appeal Tribunal of Canada from 2010 to 2017. He was appointed Queen's Counsel in 2017.

Laurel K. Taylor, BSc, MBA, PhD
Edmonton, Alberta

Laurie is currently the Corporate Director, Quality, Patient Safety & Experience at Covenant Health, which provides acute and continuing care programs and services across the province of Alberta. Her educational background includes completion of a BSc (Eng), an MBA, and a PhD (Business). Following a number of years as an engineer in the oil and gas sector, her MBA led her to a position in healthcare administration. Following the completion of her doctoral program at the University of Alberta, Laurie went on to a post-doctoral fellowship at McGill University, focusing on physician practice patterns during both programs. She was subsequently awarded a Harkness Fellowship in Health Policy with The Commonwealth Fund. She has experience in academia, research, and healthcare administration.

HYPERTENSION CANADA COMMITTEE LIST

The role of a committee is to assist the board in the decision-making process by providing needed information. There are numerous committees that work in different areas. If you're interested in joining any of these committees, contact the office at info@hypertension.ca.



D. Morris
Committee Chair

Awards Committee

The Awards Committee does the pre-work of the board for the selection process for our annual recognition awards. The committee reviews the submission of names of recommended award recipients, as well as awards policy and criteria.



R. McDonald
Committee Chair

Membership Committee

The Membership Committee is a standing committee of the Board of Directors, established to assist the board in fulfilling its oversight responsibilities in regards to membership reporting, membership policies, strategies and activities, and overall membership recruitment and retention.



Dr. S. Hiremath
Committee Chair



Dr. K. Terenzi
Co-Chair



Dr. D. Burger
Co-Chair



Dr. R. Tsuyuki
Committee Chair



D. Morris
Chair



Dr. L. Taylor
Co-Chair

Device Recommendation Committee

Hypertension Canada's BPM Device Program assists Canadians, health care professionals, and organizations in their purchasing decisions related to home, clinical and ambulatory blood pressure measurement devices. Its goals include informing healthcare professionals and the public about BPM devices that have been properly validated and recommended by Hypertension Canada to improve the accuracy of blood pressure readings.

CHC Planning Committee


The CHC (Canadian Hypertension Congress) Planning Committee is established to set the goals for and guide the planning of Hypertension Canada's annual scientific congress, the only national congress focused solely on hypertension. Its objective is to build and strengthen the Canadian Hypertension Congress' appeal and value to increase attendance and revenue.

Education and Implementation Committee

The Education and Implementation Committee is an operations sub-committee established to build Hypertension Canada's value and reputation as the trusted hypertension resource. The committee also creates needs-based education materials for increased healthcare professional and patient adoption of the Hypertension Canada Guidelines.

Governance Committee

The Governance Committee is a standing committee of the Board of Directors, established to recommend committee structure and composition, nominees for the board, and standing committee appointments. It also makes decisions on required policies, processes, and by-law revisions to support the decision-making model.



Dr. D. Rabi
Co-Chair



Dr. S. Daskalopoulou
Co-Chair

Guidelines Committee

The Guidelines Committee is established to build the Hypertension Canada Guidelines. The committee encourages innovation in Hypertension Canada’s clinical practice guidelines process.

Research and Evaluation Committee

The Research and Evaluation Committee is an integral part of the guidelines cycle. The committee’s primary goal is to promote hypertension research with a focus on surveillance, treatment, and control. The committee also provides impact numbers on the landscape of hypertension guidelines, and identifies the impact of specific health behavior recommendations and/or changes in society.



Dr. A. Leung
Committee Chair

**AWARDS
COMMITTEE**

Members of the 2022 committee:

- Dorothy Morris (Chair)
- Dr. Swapnil Hiremath
- Dr. Pavel Hamet
- Dr. Donna McLean
- Dr. Ellen Burgess
- Dr. Ricky Turgeon
- Dr. Ross Feldman

Annual Priorities and Goals that Support the Strategic Plan:

- The Awards Committee, as established by the BOD, does the pre-work in the selection process for the annual recognition awards, and then puts their decisions forward to the BOD for approval.

Update on Current Activities, Accomplishments and Initiatives:

- The Awards Committee met August 8th, where the following was decided and subsequent letters were sent out to the successful award winners:
 - Dr. Sheldon Tobe – George Fodor Award
 - Dr. Sophia Ahmed – Senior Investigator Award
 - Dr. Marianne Bertagnoli – Jacques de Champlain New Investigator Award
 - Dr. Dylan Burger – Outstanding Volunteer Award
 - Certificate of Excellence went to the Ottawa Hospital HTN program

Next Steps and Focus for the Next Year:

- The awards cycle will begin again in the summer of 2023.
- Need to establish a new committee chair to replace Dorothy Morris.

**MEMBERSHIP
COMMITTEE**

Members of the 2022 committee:

- Reid McDonald (Chair)
- Dr. Donna McLean
- Dr. Dylan Burger
- Dr. Ross Tsuyuki
- Keila Turino Miranda

Annual Priorities and Goals that Support the Strategic Plan:

- Increasing new memberships
- Retaining current memberships

Update on Current Activities, Accomplishments and Initiatives:

- Member Value Proposition
 - Over the past year we have worked to develop ideas around what members would perceive as valuable and how we can provide that to them.
- Standardised renewal year
 - All members run in a set cycle rather than the date that someone purchases a membership.
- The member referral program was created.

Next Steps and Focus for the Next Year:

- Reach out to different groups to gain new members.
- Monitor membership numbers to ensure retention and growth of membership.

DEVICE RECOMMENDATION COMMITTEE

Members of the 2022 committee:

- Dr. Swapnil Hiremath (Chair)
- Dr. Marcel Ruzicka
- Dr. Remi Goupil
- Dr. Mark Gelfer
- Dr. Laura Kuyper
- Dr. Ross Tsuyuki
- Dr. Karen Tran
- Dr. Jennifer Ringrose

Update on Current Activities, Accomplishments and Initiatives:

- In summer 2022 the program relaunched and informed manufacturers that the 'Silver category would be phased out. We have given manufacturers a 24 month warning and there will be no Silver category as of July 2024.
- Until now, only peer-reviewed publications were accepted for validation proof. After discussion, the committee decided to accept unpublished data, as long as the validation was performed by an external independent organization, and sufficient details are available for the reviewers to make the judgment. A checklist has been designed to help the reviewers and keep record of the process for HC. Additionally, manufacturers have been informed of journals that do publish validation papers (Blood Pressure Monitoring; and Canadian Journal Of Cardiology Open).
- The HC office has developed and sent out a message to pharmacists and retailers on the advantages of selling a validated blood pressure monitor.

- We plan to reach out to health communities, nurses, and physicians to inform them about Hypertension Canada's device validation standards and other information on the website.

- Presently the website (<https://hypertension.ca/bpdevices>) has 5 ABPM (all Gold), 4 clinic grade (1 Silver, 3 Gold), 70 Home BP (36 Gold, 34 Silver) and 9 BP kiosk (all Gold) devices listed.

- These continue to be a strong revenue source.

Next Steps and Focus for the Next Year:

- Increase awareness of the importance of validation in the wider community. There are non-validated devices available for sale online and through retailers (eg <https://jamanetwork.com/journals/jama/fullarticle/2789043>) and a study is being planned to examine this in Canada.
- We are planning to do a lecture on BP validation and its importance at the next Canadian Hypertension Congress.
- We will roll out the checklist for the standardization of the review process, and allow unpublished but validated devices to be reviewed.

EDUCATION AND IMPLEMENTATION COMMITTEE

Members of the 2022 committee:

- Dr. Ross Tsuyuki (Chair)

Annual Priorities and Goals that Support the Strategic Plan:

- A set of HC 2020 guidelines slides was created.
- We created a pharmacy curriculum based upon the 2020 guidelines.
- Implementation Science initiative – taking a systematic approach to implementation of the Hypertension Canada 2020 guidelines.
- There have been discussions with Guidelines committee to merge – less emphasis on making guidelines, more emphasis on dissemination and implementation.

Update on Current Activities, Accomplishments and Initiatives:

- We developed a slide set for the HC 2020 guidelines, and posted them on the HC website in both English and French.
- Dr. Arden Barry (University of British Columbia) has developed a hypertension curriculum for pharmacy students based upon the HC 2020 guidelines. We have translated it into French and posted both on the HC website.
- Implementation Science initiative to improve uptake of the HC guidelines, entitled "Leveraging Implementation and Behavioural Science to Improve Hypertension Management in Women by Primary Care Clinicians."

- We have recruited Dr. Kaitlyn Watson as a postdoctoral research fellow for this project. She is co-supervised by Dr. Jeremy Grimshaw and Dr. Ross Tsuyuki.

- We started work on this project in February 2022 by meeting with patient partners and primary care clinicians.

- Dr. Watson received the prestigious Health System Impact Fund award from the Canadian Institutes of Health Research for this work.

- Guidelines presentations have been presented to Shoppers Drug Mart, Save on Foods annual pharmacist meetings, Pharmacy U (Vancouver), and the Alberta Pharmacists Association.

Next Steps and Focus for the Next Year:

- Restart work on the Implementation Science initiative.
- Dissemination of the pharmacy curriculum to all pharmacy schools.
- Determine if there is interest in adapting the pharmacy curriculum into a nursing curriculum.
- We will continue discussions with the Guidelines Committee regarding a merger of committees and activities.

GOVERNANCE COMMITTEE

Members of the 2022 committee:

- Dorothy Morris (Chair)
- Dr. Laurie Taylor (Co-Chair)
- Dr. Ross Tsuyuki

Annual Priorities and Goals that Support the Strategic Plan:

- As a Governance Committee, we recommend the organizational board and committee structure/composition. We review required policies, processes, and by-law revisions to support the decision-making model.

Update on Current Activities, Accomplishments and Initiatives:

- Three meetings took place this past year.
- The committee accepted the resignations of Dr. Rob Gros, Dr. Alan Bell (competing clinical and research workloads) and Janusz Kraczkowski (8 year term).
- Laurie Taylor agreed to chair this Committee, starting after the September BOD meeting. Although Dorothy will remain on the committee, her 8 year term as a member of the BOD is up.
- Terms of Reference for the Governance Committee were reviewed. The Conflict of Interest Policy and Code of Conduct Policy have also been reviewed and updated.

- A lawyer who specializes in non-profit organizations has been hired by Asif to ensure our bylaws are compliant with Ontario's new legislation with respect to non-profits (compliance required by 2024).

- Three applicants for the board were interviewed.

- We welcome Paul Broconnier, a retired Chartered Accountant, to the BOD as our new treasurer.

- Dr. Jill Bruneau, a Nurse Practitioner from St. Johns Newfoundland, will replace Dr. Bell. Dr. Bruneau has extensive clinical experience, is passionate about the detection and timely management of hypertension, and comes with previous board experience with the Canadian Council of Cardiovascular Nurses. We welcome Dr. Bruneau to the BOD.

- The newly created board position for patient engagement will be filled by Ms. Kerri Eady (BA) Hons Managerial Economics. Kerri has extensive experience in business in sales/marketing/quality assurance. In addition, she has a personal interest in hypertension and its management. We welcome Ms. Eady to the BOD.

Next Steps and Focus for the Next Year:

- Orientation for all the members of the BOD.
- A task force is being organized by Asif for a review of the website to ensure we are the trusted voice in Canada for Hypertension and CV risk.

GUIDELINES COMMITTEE

Members of the 2022 committee:

- Dr. Doreen Rabi (Co-Chair)
- Dr. Stella Daskalopoulou (Co-Chair)

Annual Priorities and Goals that Support the Strategic Plan:

- Maintain a high profile for Hypertension Canada as a trusted source of guidance for hypertension diagnosis and care.
- Continue to advance care for people with hypertension in Canada by developing needed guidelines when new evidence or clinical need demands.
- Provide opportunities for emerging leaders in hypertension research and care to engage in the guideline development process.

Update on Current Activities, Accomplishments and Initiatives:

- The Guidelines Committee continues to work on completing reviews of highly desired topics in hypertension for Canadian healthcare professions. The review on gender-specific issues in diagnosis and management is near completion (and the protocol has been published). The protocol for the review on the diagnosis and management of severe asymptomatic hypertension and accelerated hypertension has been developed. Strategically, focusing on topics that fill specific gaps in practice is essential to evolve the guidelines.
- Partnering with patients and primary care is also critical to ensure our guidelines are meeting the needs of our users, and ultimately,

are more effective at achieving our organizational goal of reducing morbidity and mortality related to hypertension. In this regard, the committee continues to work collaboratively with the Implementation and Education Committee to understand the challenges that patients and primary care face when trying to use our guidelines.

Next Steps and Focus for the Next Year:

- We will work with Dr. Tsuyuki and the board to finalize a contract with the McMaster Evidence Center so we can move forward with completing comprehensive, rigorous reviews in a more timely way.
- We will be working with the WHO to identify clinical and research gaps in the field of hypertension at an international level.
- We will continue to engage and grow our international partnerships.
- We will continue to explore how we can better incorporate social determinants of health and structural, cultural, and political contributors to hypertension into our guidance.
- Operationally, we have had a few challenges with respect to the loss of a staff librarian who assisted with developing valid search strategies for our reviews, however, we are now in discussions with the McMaster Evidence Center to engage their team to assist with both search strategy development and reviewing evidence for relevance to our guidelines. Employing this team to support these activities

will ensure rigor in process as it will ensure standardization and protocolization of our evidence reviews. This will also enhance efficiency as our clinician volunteers have several demands on their time and will ensure we engage them only in activities that require their specific expertise (namely, drafting the guidelines, approving guidelines via consensus, and drafting manuscripts/statements). This partnership with the McMaster Evidence Center will require funds; the estimated budget will be forthcoming.

- Our team also lost a dedicated educational consultant (Rebecca Sedore) in 2020. Rebecca (and Susan Carter before her) was essential in helping move projects along. The Chairs have felt this loss significantly, particularly as we have been clinically very preoccupied with pandemic management. We appreciate Dr. Tsuyuki's understanding of this, and we are working with the administrative team to address this particular operational challenge.

RESEARCH AND EVALUATION COMMITTEE

Members of the 2022 committee:

- Dr. Alexander Leung (Chair)
- Dr. Hude Quan
- Dr. Finlay McAlister
- Dr. Karen Tran
- Dr. Nadia Khan
- Dr. Norm Campbell

Annual Priorities and Goals that Support the Strategic Plan:

- Surveillance of key indicators for hypertension, including prevalence, awareness, treatment, and control, as data becomes available.
- Provide ad hoc support for relevant research opportunities identified by the Guidelines Committee, and the Education and Implementation Committee.

Update on Current Activities, Accomplishments and Initiatives:

- We published a report on the national prevalence of resistant hypertension and its associated comorbidities (Can J Cardiol. 2022 May;38:681-687).
- Created a description of the epidemiology of hypertension among children and adolescents in Canada according to recent definitions given by clinical practice guidelines (in process).
- Update on the prevalence, awareness, treatment, and control rates for hypertension in Canada using the Canadian Health Measures Survey with data up to cycle 6 (2018-2019) (in process).

Next Steps and Focus for the Next Year:

- Publish epidemiology of pediatric hypertension in Canada.
- Complete update on key indicators for hypertension in Canada.

FINANCIAL
OVERVIEW





2022 FINANCIAL OVERVIEW

Trevor Hudson

Our results for the fiscal year ended on April 30, 2022 ended strong with growth in our earnings and net assets. This is a continuation of the positive trend we saw last year and is a function of growth in our revenue streams and diligent cost management. The audit for the 2022 fiscal year has been completed and we have received an unqualified opinion on the financial statements. Furthermore, there were no unadjusted errors and post-closing adjusting journal entries were minimal and immaterial.


Net income for fiscal 2022 was \$342,193, comprised of operational income of \$486,177 offset by an unrealized loss of \$143,984, resulting from volatility in the financial markets. Revenue for the year was \$852,064, a \$446,672 increase over prior year, driven primarily by payments collected from our device recommendation program, grants and sponsorships, realized investment income, membership dues, and professional certification program fees. Our expenses for the year were \$365,887, as compared to \$446,323 in prior year, the decrease attributable to the elimination of salaries and benefits, as well as the write off

for obsolete property and equipment. Furthermore, there were no bad debt expenses on receivables. Our balance sheet continued to strengthen with assets of \$2,774,470, an increase of \$305,783 over prior year.

In fiscal 2022, cash balances increased from \$30,564 to \$353,950, while current liabilities decreased from \$72,983 to \$36,573, contributing to strong liquidity and a surplus of cash beyond our current operational needs. On the recommendation of the finance committee, the board voted on June 24, 2022 to transfer cash of \$250,000 to the Research Fund. As a reminder, a significant amount was transferred from the Research Fund in previous years in order to fund operational needs. To that end, the board is committed to replenishing the Research Fund in order to sustain our organizational mandate for future years.

In summary, our financial position has continued to improve and we continue to reverse the deficit incurred in previous years. While the financial markets continue to show volatility in the current economic environment our operational focus and financial prudence has contributed to organizational stability and a positive outlook for our future.

J. Trevor Hudson, BSc, MBA, MTax, CPA, CA
Treasurer



Hypertension CANADA

**CONTACT
INFORMATION**

65 Overlea Boulevard
Suite 240
Toronto, Ontario
M4H 1P1

PHONE
(905) 943-9400

EMAIL
info@hypertension.ca

WEBSITE
www.hypertension.ca